RIM
ALXN

Rainier Investment Management’s Alexion Pharmaceuticals ALXN Stock Holding History

Rainier Investment Management’s Portfolio ALXN Stock Details ALXN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		– Sell
-9,610
Closed -$1.35M – 133
2017
Q3 		$1.35M Sell
9,610
-3,080
-24% -$418K 0.32% 111
2017
Q2 		$1.54M Sell
12,690
-10,170
-44% -$1.18M 0.31% 118
2017
Q1 		$2.77M Sell
22,860
-9,705
-30% -$1.25M 0.3% 130
2016
Q4 		$3.98M Sell
32,565
-29,030
-47% -$3.55M 0.39% 112
2016
Q3 		$7.55M Sell
61,595
-20,120
-25% -$2.59M 0.49% 89
2016
Q2 		$9.54M Sell
81,715
-6,440
-7% -$914K 0.46% 92
2016
Q1 		$12.3M Buy
88,155
+7,880
+10% +$1.16M 0.55% 73
2015
Q4 		$15.3M Buy
80,275
+6,690
+9% +$1.17M 0.6% 70
2015
Q3 		$11.5M Sell
73,585
-30,190
-29% -$5.51M 0.42% 113
2015
Q2 		$18.8M Sell
103,775
-113,570
-52% -$19.6M 0.59% 64
2015
Q1 		$37.7M Buy
217,345
+57,635
+36% +$10.4M 0.75% 46
2014
Q4 		$29.6M Buy
+159,710
New +$29.6M 0.53% 75

Other funds holding ALXN

T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Rainier Investment Management's ALXN Position: Q4 2017 in Review

Rainier Investment Management sold out of Alexion Pharmaceuticals (ALXN) in Q4 2017, closing a stake of 9,610 shares — an estimated $1.35M sold.

Rainier Investment Management first reported a position in ALXN in Q4 2014 and held it in 12 quarters. The position peaked at $37.7M in Q1 2015. 587 funds tracked by Wall St. Rank hold ALXN as of Q4 2017.

  • Rainier Investment Management reported no remaining Alexion Pharmaceuticals position as of Q4 2017 after selling out during the quarter.
  • Rainier Investment Management sold 9,610 Alexion Pharmaceuticals shares in Q4 2017, an estimated $1.35M.
  • Rainier Investment Management first reported a position in Alexion Pharmaceuticals in Q4 2014 and held it in 12 quarters.
  • Rainier Investment Management's Alexion Pharmaceuticals position peaked at $37.7M in Q1 2015.
  • 587 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q4 2017.

Based on Rainier Investment Management's 13F filing for Q4 2017, filed 2 Feb 2018.